NCT04533048View on ClinicalTrials.gov

A Clinical Study to Evaluate MW33 Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

December 2, 2020

Conditions
Covid19
Interventions
COMBINATION_PRODUCT

MW33 injection

a recombinant fully human antibody to coronavirus

COMBINATION_PRODUCT

MW33 injection placebo

Placebo

Trial Locations (1)

Unknown

Shanghai Public Health Clinical Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Public Health Clinical Center

OTHER_GOV

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY

NCT04533048 - A Clinical Study to Evaluate MW33 Injection | Biotech Hunter | Biotech Hunter